Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kristine Lacuna

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Frontiers in Oncology|March 27, 2023
Therapeutic advances in leiomyosarcomaKristine Lacuna, Sminu Bose, Matthew Ingham, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 30, 2023
State of the Art: Multidisciplinary Management of Oligometastatic Renal Cell CarcinomaShawn Dason, Kristine Lacuna, Raquibul Hannan, et al.
Physiology & Behavior|July 6, 2010
Differential effects of sucrose and fructose on dietary obesity in four mouse strainsJohn I Glendinning, Lindsey Breinager, Emily Kyrillou, et al.
JAMA Dermatology|July 30, 2025
Use of Dupilumab to Manage Antibody-Drug Conjugate-Induced Cutaneous ToxicitiesIan Nykaza, Stephen W Dusza, Jonathan E Rosenberg, et al.
European Urology Oncology|August 19, 2022
Erratum to "Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503)" [Eur Urol Oncol 2021;4:543-52]Michael J Morris, Jose Mauricio Mota, Kristine Lacuna, et al.
European Urology Oncology|May 22, 2021
Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503)Michael J Morris, Jose Mauricio Mota, Kristine Lacuna, et al.
JCO Precision Oncology|September 24, 2025
Clinical and Pathologic Landscapes of Delta-Like Ligand 3 and Seizure-Related Homolog Protein 6 Expression in Neuroendocrine CarcinomasJessica S Ross, Rohit Thummalapalli, Kristine Lacuna, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 9, 2013
Phase I pharmacokinetic and biodistribution study with escalating doses of ²²³Ra-dichloride in men with castration-resistant metastatic prostate cancerJorge A Carrasquillo, Joseph A O'Donoghue, Neeta Pandit-Taskar, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Frontiers in Oncology|March 27, 2023
Therapeutic advances in leiomyosarcomaKristine Lacuna, Sminu Bose, Matthew Ingham, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 30, 2023
State of the Art: Multidisciplinary Management of Oligometastatic Renal Cell CarcinomaShawn Dason, Kristine Lacuna, Raquibul Hannan, et al.
Physiology & Behavior|July 6, 2010
Differential effects of sucrose and fructose on dietary obesity in four mouse strainsJohn I Glendinning, Lindsey Breinager, Emily Kyrillou, et al.
JAMA Dermatology|July 30, 2025
Use of Dupilumab to Manage Antibody-Drug Conjugate-Induced Cutaneous ToxicitiesIan Nykaza, Stephen W Dusza, Jonathan E Rosenberg, et al.
European Urology Oncology|August 19, 2022
Erratum to "Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503)" [Eur Urol Oncol 2021;4:543-52]Michael J Morris, Jose Mauricio Mota, Kristine Lacuna, et al.
European Urology Oncology|May 22, 2021
Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503)Michael J Morris, Jose Mauricio Mota, Kristine Lacuna, et al.
JCO Precision Oncology|September 24, 2025
Clinical and Pathologic Landscapes of Delta-Like Ligand 3 and Seizure-Related Homolog Protein 6 Expression in Neuroendocrine CarcinomasJessica S Ross, Rohit Thummalapalli, Kristine Lacuna, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 9, 2013
Phase I pharmacokinetic and biodistribution study with escalating doses of ²²³Ra-dichloride in men with castration-resistant metastatic prostate cancerJorge A Carrasquillo, Joseph A O'Donoghue, Neeta Pandit-Taskar, et al.
Pageof 1